Duration of any effect is poorly characterised. Short-term improvements in bone-marker biochemistry (osteocalcin, P1NP) have persisted for 6–18 months post-infusion in some reports, but most studies lack long-term follow-up beyond 24 months. Bone remodelling is a continuous process, so maintenance of benefit may require periodic retreatment.
Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material. Osteoporosis occurs when remodelling becomes imbalanced, with too much removal and insufficient replacement, leaving a porous, fragile architecture vulnerable to fracture. Placental mesenchymal stem cells have attracted research interest because they can differentiate into osteoblasts, potentially helping restore bone-forming capacity. The mechanism appears to involve both direct cellular replacement of bone-building cells and the release of signalling molecules (cytokines) that shift the remodelling ratio back toward deposition. Early-stage trials are exploring whether cell therapy can slow or partially reverse the density loss that typically accelerates after oestrogen withdrawal in post-menopausal women, though robust efficacy data remain limited.
Am I a candidate? → · Osteoporosis & Bone Health: full overview → · Osteoporosis & Bone Health cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment